Effect of L-(αS,5S)-α-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid on urinary excretion of methylmercury in the mouse

Kathleen Mulder, P. J. Kostyniak

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The γ-GTP inhibitor L-(αS,5S)-α-amino-3-chloro-4,5-dihydro-5- isoxazoleacetic acid (AT-125) was administered to CBA/J mice pretreated with 203Hg-methylmercury (MM) (0.5 mg/kg) to determine whether increasing urinary GS in this strain would result in a simultaneously increased urinary elimination of MM. Doses at AT-125 ranging from 3.0 to 30 mg/kg increased urinary GS in a dose-related fashion. The peak effect was attained at 2 hr after injection. AT-125 (7.5 mg/kg) increased urinary GS to peak value of 450 μM. When this dose was administered to mice 24 hr after MM, neither the rate of decline in body burden of 203Hg nor the rate of 203Hg output into urine or feces varied significantly from control values. A dose of 15 mg of AT-125 per kg increased urinary GS to 1.0 mM and caused a significant increase in urinary excretion of 203Hg when compared to the 7.5-mg dose group. The greatest effect was seen at the 30-mg AT-125/kg dose which produced a 1.9 mM concentration of total GS in urine and a 2-fold increase in the urinary 203Hg excretion rate. The dose-dependent changes in urinary excretion elicited by AT-125 were paralleled by increased rates of decline of 203Hg body burden and decreased rates of excretion in the feces. The results suggest that urinary GS must approach the millimolar range before affecting a redistribution of MM across the luminal membrane.

Original languageEnglish (US)
Pages (from-to)156-160
Number of pages5
JournalJournal of Pharmacology and Experimental Therapeutics
Volume234
Issue number1
StatePublished - 1985

Fingerprint

acivicin
Acids
Body Burden
Feces
Urine
Hairless Mouse
Inbred CBA Mouse
Guanosine Triphosphate
Injections

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

@article{2ec4429f0a39482d98ddd5778250f067,
title = "Effect of L-(αS,5S)-α-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid on urinary excretion of methylmercury in the mouse",
abstract = "The γ-GTP inhibitor L-(αS,5S)-α-amino-3-chloro-4,5-dihydro-5- isoxazoleacetic acid (AT-125) was administered to CBA/J mice pretreated with 203Hg-methylmercury (MM) (0.5 mg/kg) to determine whether increasing urinary GS in this strain would result in a simultaneously increased urinary elimination of MM. Doses at AT-125 ranging from 3.0 to 30 mg/kg increased urinary GS in a dose-related fashion. The peak effect was attained at 2 hr after injection. AT-125 (7.5 mg/kg) increased urinary GS to peak value of 450 μM. When this dose was administered to mice 24 hr after MM, neither the rate of decline in body burden of 203Hg nor the rate of 203Hg output into urine or feces varied significantly from control values. A dose of 15 mg of AT-125 per kg increased urinary GS to 1.0 mM and caused a significant increase in urinary excretion of 203Hg when compared to the 7.5-mg dose group. The greatest effect was seen at the 30-mg AT-125/kg dose which produced a 1.9 mM concentration of total GS in urine and a 2-fold increase in the urinary 203Hg excretion rate. The dose-dependent changes in urinary excretion elicited by AT-125 were paralleled by increased rates of decline of 203Hg body burden and decreased rates of excretion in the feces. The results suggest that urinary GS must approach the millimolar range before affecting a redistribution of MM across the luminal membrane.",
author = "Kathleen Mulder and Kostyniak, {P. J.}",
year = "1985",
language = "English (US)",
volume = "234",
pages = "156--160",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Effect of L-(αS,5S)-α-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid on urinary excretion of methylmercury in the mouse

AU - Mulder, Kathleen

AU - Kostyniak, P. J.

PY - 1985

Y1 - 1985

N2 - The γ-GTP inhibitor L-(αS,5S)-α-amino-3-chloro-4,5-dihydro-5- isoxazoleacetic acid (AT-125) was administered to CBA/J mice pretreated with 203Hg-methylmercury (MM) (0.5 mg/kg) to determine whether increasing urinary GS in this strain would result in a simultaneously increased urinary elimination of MM. Doses at AT-125 ranging from 3.0 to 30 mg/kg increased urinary GS in a dose-related fashion. The peak effect was attained at 2 hr after injection. AT-125 (7.5 mg/kg) increased urinary GS to peak value of 450 μM. When this dose was administered to mice 24 hr after MM, neither the rate of decline in body burden of 203Hg nor the rate of 203Hg output into urine or feces varied significantly from control values. A dose of 15 mg of AT-125 per kg increased urinary GS to 1.0 mM and caused a significant increase in urinary excretion of 203Hg when compared to the 7.5-mg dose group. The greatest effect was seen at the 30-mg AT-125/kg dose which produced a 1.9 mM concentration of total GS in urine and a 2-fold increase in the urinary 203Hg excretion rate. The dose-dependent changes in urinary excretion elicited by AT-125 were paralleled by increased rates of decline of 203Hg body burden and decreased rates of excretion in the feces. The results suggest that urinary GS must approach the millimolar range before affecting a redistribution of MM across the luminal membrane.

AB - The γ-GTP inhibitor L-(αS,5S)-α-amino-3-chloro-4,5-dihydro-5- isoxazoleacetic acid (AT-125) was administered to CBA/J mice pretreated with 203Hg-methylmercury (MM) (0.5 mg/kg) to determine whether increasing urinary GS in this strain would result in a simultaneously increased urinary elimination of MM. Doses at AT-125 ranging from 3.0 to 30 mg/kg increased urinary GS in a dose-related fashion. The peak effect was attained at 2 hr after injection. AT-125 (7.5 mg/kg) increased urinary GS to peak value of 450 μM. When this dose was administered to mice 24 hr after MM, neither the rate of decline in body burden of 203Hg nor the rate of 203Hg output into urine or feces varied significantly from control values. A dose of 15 mg of AT-125 per kg increased urinary GS to 1.0 mM and caused a significant increase in urinary excretion of 203Hg when compared to the 7.5-mg dose group. The greatest effect was seen at the 30-mg AT-125/kg dose which produced a 1.9 mM concentration of total GS in urine and a 2-fold increase in the urinary 203Hg excretion rate. The dose-dependent changes in urinary excretion elicited by AT-125 were paralleled by increased rates of decline of 203Hg body burden and decreased rates of excretion in the feces. The results suggest that urinary GS must approach the millimolar range before affecting a redistribution of MM across the luminal membrane.

UR - http://www.scopus.com/inward/record.url?scp=0021810648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021810648&partnerID=8YFLogxK

M3 - Article

C2 - 4009498

AN - SCOPUS:0021810648

VL - 234

SP - 156

EP - 160

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 1

ER -